
|Articles|August 15, 2003
Topical drop handles moderate inflammation associated with KCS
Fort Lauderdale, FL-Topical loteprednol etabonate 0.5% (Lotemax, Bausch & Lomb) instilled four times daily may be beneficial to treat patients who have keratoconjunctivitis sicca (KCS) with at least a moderate inflammatory component.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
3
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


